Pharmaceutical Management of Ovarian Cancer
- 1 January 2008
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 68 (6), 771-789
- https://doi.org/10.2165/00003495-200868060-00004
Abstract
Over recent decades, truly impressive progress has been made in the outcome associated with the pharmacological antineoplastic management of women with advanced ovarian cancer. Following initial...Keywords
This publication has 131 references indexed in Scilit:
- A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: The Finnish Ovarian Cancer (FINOVA) studyEuropean Journal Of Cancer, 2006
- Chronic Administration of Single-Agent Paclitaxel in Gynecologic MalignanciesGynecologic Oncology, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: enhancement of DNA platination as a possible mechanismCancer Letters, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- The impact of received dose intensity on the outcome of advanced ovarian cancerEuropean Journal Of Cancer, 1993
- Analysis of prognostic factors in stage I epithelial ovarian carcinoma: Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapseAmerican Journal of Obstetrics and Gynecology, 1993
- A southwest oncology group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancerCancer, 1991
- Acute Nonlymphocytic Leukemia after Therapy with Alkylating Agents for Ovarian CancerNew England Journal of Medicine, 1982
- Advanced Ovarian AdenocarcinomaNew England Journal of Medicine, 1978